This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): panitumumab, ABX-EGF
Description: Vectibix is a XenoMouse-generated fully human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) with high affinity. Other drugs that impact this target are ImClone’s Erbitux (also a monoclonal antibody) and the small molecules Iressa from AstraZeneca and Tarceva from OSI, Roche, and Genentech. Iressa was the first approved EGFR inhibitor.
Revenue splits are BioMedTracker estimates.
Immunex (Amgen) and Abgenix
In July 2000, Abgenix entered into a joint development and commercialization agreement with Immunex. Immunex was acquired by Amgen in 2002.
Amgen/Immunex paid Abgenix a license fee and will pay certain milestone fees. Amgen/Immunex and Abgenix will share responsibilities for phase II trials while Immunex will be responsible for phase III trials. Both Amgen/Immunex and Abgenix will have co-markeitng rights. Amgen/Immunex have been successful at designing and conducting phase III clinical trials. This co-development agreement decreases the risk that ABX-EGF's approval will be denied or delayed due to poorly designed or executed clinical trials.
Amgen completed its acquisition of Abgenix in April, 2006. Amgen acquired Abgenix for a total cash consideration of approximately $2.2 billion plus assumed debt. Amgen paid stockholders of Abgenix $22.50 in cash per share of common...See full deal structure in Biomedtracker
Partners: Takeda Pharmaceutical Company Ltd Beta Pharma Inc.
Additional information available to subscribers only: